Welcome to CKB CORE's new home! Please be sure to update any bookmarks you may have.
×

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05440864
Title Durvalumab and Tremelimumab in Resectable HCC ((NEOTOMA))
Acronym (NEOTOMA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications
Therapies
Age Groups: senior | adult
Covered Countries ITA | ESP | CAN


No variant requirements are available.